Probiotics for pediatric functional abdominal pain: which strains have evidence

← Back to articles

Recurrent abdominal pain affects an estimated 10–20% of school-age children. Under the Rome IV framework, most cases without an identifiable organic cause are classified as functional abdominal pain disorders (FAPDs): irritable bowel syndrome (IBS), functional abdominal pain–not otherwise specified, functional dyspepsia, and abdominal migraine. The pathophysiology is multi-factorial — visceral hypersensitivity, altered gut motility, microbiota differences, and gut-brain signaling all appear to contribute. Because the gut microbiome is implicated, probiotics are a biologically plausible adjunct, and several dozen pediatric trials have now been run. The honest summary is that the effect, where it exists, is modest and strain-specific: a few well-defined strains show a small benefit, most marketed products have never been tested, and the overall certainty of evidence is low.

The most-studied strain: Lactobacillus rhamnosus GG

LGG has the largest single-strain evidence base in pediatric FAPDs. The foundational trial randomized 104 children meeting Rome II criteria for functional dyspepsia, IBS, or FAP to LGG or placebo for 4 weeks. Across the whole group, treatment success (no pain) was more common with LGG than placebo (25% versus 9.6%; relative benefit 2.6, 95% CI 1.05–6.6; number needed to treat 7). The effect was concentrated in the IBS subgroup, where success reached 33% versus 5% (NNT 4) with reduced pain frequency; children with functional dyspepsia or non-IBS functional pain saw no benefit [1]. A 2011 meta-analysis pooling three LGG RCTs (290 children) confirmed this pattern — a significantly higher responder rate overall (RR 1.31, 95% CI 1.08–1.59) that was driven almost entirely by the IBS subgroup (RR 1.70, 95% CI 1.27–2.27) [2]. The takeaway is narrow but real: LGG helps a minority of children, mostly those with an IBS phenotype.

Lactobacillus reuteri DSM 17938

L. reuteri DSM 17938 — best known for its evidence in breastfed infants with colic — has also been tested in older children with FAP. A 2010 double-blind RCT randomized 60 children aged 6–16 with Rome III FAP to L. reuteri DSM 17938 (2×10⁸ CFU/day) or placebo for 4 weeks; the treatment group reported significantly lower pain intensity [3]. A 2017 RCT in 55 children with FAP or IBS found more pain-free days with L. reuteri (median 89.5 versus 51 days) and lower pain severity in the second and fourth months, although duration of pain and school absence did not differ [4]. The L. reuteri evidence base is smaller than LGG's and the trials are individually small, but the direction is consistent.

VSL#3 (now sold as Visbiome) — multi-strain

The high-potency multi-strain formulation containing eight species (four Lactobacillus, three Bifidobacterium, and Streptococcus thermophilus) has one supportive pediatric IBS trial. A 2010 multicenter, randomized, double-blind, placebo-controlled crossover study in 59 children with IBS found VSL#3 superior to placebo for the primary endpoint (subjective symptom relief) and for abdominal pain, bloating, and family-assessed quality of life, over a 6-week treatment period [5]. The product is well-characterized, but it is a single trial, the placebo response was substantial, and the daily dose (hundreds of billions of CFU per sachet) is far higher and more expensive than single-strain options.

Strains and products without convincing pediatric evidence

Saccharomyces boulardii has good pediatric evidence for antibiotic-associated and acute infectious diarrhea, but its data in FAPDs are limited and inconsistent [6]. Bifidobacterium infantis 35624, an adult IBS strain, has not been studied to a comparable depth in children. Critically, most over-the-counter "kids' probiotic" gummies and powders use undisclosed or proprietary strain blends that have never been tested in any pediatric FAPD trial. Because probiotic effects do not generalize across strains — even within the same species — a high "billions of CFU" count on the label tells you nothing about whether that particular product works for abdominal pain.

What the pooled evidence actually shows

The 2023 Cochrane review of probiotics for pediatric FAPDs pooled 18 RCTs (1,309 children) and found that probiotics may produce more treatment success than placebo at the end of treatment — roughly 50% versus 33% (RR 1.57, 95% CI 1.05–2.36) — but rated this as low-certainty evidence because of high inconsistency and risk of bias, and could not draw firm conclusions about complete pain resolution or about pain frequency and severity [7]. A 2025 Lancet Child & Adolescent Health network meta-analysis of 91 trials reached a sobering conclusion: only psychological therapies (hypnotherapy and cognitive behavioral therapy) reached moderate-certainty evidence of benefit, while probiotics and most other treatments could not be distinguished from control at acceptable certainty [8]. In other words, probiotics may help a little, but the strongest evidence in this condition is for brain-gut behavioral therapies.

Mechanisms that may matter

Pediatric FAPDs are thought to involve some combination of altered intestinal permeability, low-grade mucosal immune activation, and disordered gut-brain signaling. Specific probiotic strains can strengthen epithelial tight junctions, modulate mucosal immune responses, and influence visceral pain pathways in laboratory and animal models, which provides biological plausibility for the strain-specific clinical findings — but mechanism is not proof of clinical benefit, and the human effect sizes remain small.

Practical use in children

For a child who meets Rome IV criteria for IBS or FAP and whose symptoms interfere with daily life, a time-limited (roughly 4–8 week) trial of a well-characterized strain — LGG or L. reuteri DSM 17938 at the doses used in the trials above — is a reasonable, low-risk adjunct, but only after a clinician has evaluated the child and excluded organic disease (alarm features such as weight loss, GI bleeding, nocturnal symptoms, or abnormal labs warrant work-up, not probiotics). Choose a product that names the exact strain (genus, species, and strain identifier), because results do not transfer across strains. If there is no meaningful improvement after the trial period, stopping is appropriate. Probiotics should complement, not replace, the evidence-based core of FAPD care — reassurance, dietary review, and where appropriate the behavioral therapies that carry the strongest evidence.

Safety

Probiotic supplementation is generally well tolerated in immunocompetent children; adverse events in the pooled trials were rare and no serious adverse events were reported, though randomized trials are not the ideal setting to detect rare harms [7]. Caution is warranted in immunocompromised children, those with central venous catheters, and critically ill children, in whom rare probiotic bloodstream infections have been described. Children with short-bowel syndrome or other significant GI compromise should not start probiotics without specialist input.

Sources

1. Gawrońska A, Dziechciarz P, Horvath A, Szajewska H. "A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children." Aliment Pharmacol Ther, 2007;25(2):177-184. PMID 17229242.
2. Horvath A, Dziechciarz P, Szajewska H. "Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood." Aliment Pharmacol Ther, 2011;33(12):1302-1310. PMID 21507030.
3. Romano C, Ferrau' V, Cavataio F, et al. "Lactobacillus reuteri in children with functional abdominal pain (FAP)." J Paediatr Child Health, 2010;50(10):E68-71. PMID 20626584.
4. Jadrešin O, Hojsak I, Mišak Z, et al. "Lactobacillus reuteri DSM 17938 in the Treatment of Functional Abdominal Pain in Children: RCT Study." J Pediatr Gastroenterol Nutr, 2017;64(6):925-929. PMID 27906800.
5. Guandalini S, Magazzù G, Chiaro A, et al. "VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study." J Pediatr Gastroenterol Nutr, 2010;51(1):24-30. PMID 20453678.
6. Barnes D, Yeh AM. "Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children." Nutr Clin Pract, 2015;30(6):747-759. PMID 26538058.
7. Wallace C, Gordon M, Sinopoulou V, Akobeng AK. "Probiotics for management of functional abdominal pain disorders in children." Cochrane Database Syst Rev, 2023;2(2):CD012849. PMID 36799531.
8. Sinopoulou V, Groen J, Gordon M, et al. "Efficacy of interventions for the treatment of irritable bowel syndrome, functional abdominal pain-not otherwise specified, and abdominal migraine in children: a systematic review and network meta-analysis." Lancet Child Adolesc Health, 2025;9(5):315-324. PMID 40246358.